Home > Investor Relations > Business Strategy

Business Strategy

Basic Strategy

The strength of Nippon Kayaku lies in the growing fields of information/communications, energy conservation, health care, and safety systems, and we aim to create therein the excellent value-added products and business required by this twenty-first century society. We contribute to social positively, while integrating its key technologies of explosive, dye, pharmaceutical, and resin with external technologies; and improve on fusion of technologies.

Nippon Kayaku will strive to be the number one company in this global niche market. To do so, our management strategy will have a focus toward 2016, the company's 100th anniversary, and the business fundamentals to improve profitability.

Basic Technologies and Fusion

Many of our groups' main products such as automotive sasfety components, optical functional films, polarizing films, and odors for inkjet printers have been invented through technological integration.

Various technologies have been created and their commercialization has been actively pursued.

Examples of New Technologies

  • Dye-sensitized solar cells

    This cell is regarded as very important for the next-generation solar cell in the prevention of global warming.

  • Ultrafine diamonds

    This diamond is expected to be used in various fields and such purposes as enhancing optical materials and coating.

  • Polymeric micelle anti-cancer drug

    This drug can be sent to cancer sites through the drug delivery system.

Growth Scenario Accompanied by Cooperation and Fusion

From the end of fiscal year May 31, 2005 to the end of fiscal year May 31, 2007, our highest profits have been recorded and continuous for three years due to portfolio reforms and selective and concentrated business efforts.

As for the end of fiscal year May 31, 2008, our business activities have been in a leveling-off phase due to the decreasing demand for optical functional films in the Electronic Materials Division, high price of oil and soaring prices for raw materials.

From the end of fiscal year May 31, 2010, we will concentrate on high value-added products, expand foreign business, enhance core business, intensively utilize our advantages, invest in (the development of pharmaceuticals centering on the polymeric micelle anti-cancer drug), and activate our organization by adopting a project system. Based on the above activities, we aim to achieve ROE 10% by the end of fiscal year May 31, 2013.

Back to Top